Trials / Recruiting
RecruitingNCT06188624
Clinical Trial of TQB2922 for Injection in Patients With Advanced Cancers
A Phase I Clinical Study of TQB2922 for Injection in Patients With Advanced Cancers
- Status
- Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 150 (estimated)
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This is a Phase I study to evaluate the safety, tolerability, and efficacy of TQB2922 for injection in subjects with advanced cancers
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | TQB2922 for injection | TQB2922 for injection is administrated to patients with advanced cancers, 28 days as a treatment cycle |
Timeline
- Start date
- 2024-02-01
- Primary completion
- 2026-12-01
- Completion
- 2027-12-01
- First posted
- 2024-01-03
- Last updated
- 2025-04-25
Locations
17 sites across 1 country: China
Source: ClinicalTrials.gov record NCT06188624. Inclusion in this directory is not an endorsement.